Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

Recruiting

Observational StudyRimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

Sponsor:

Medstar Health Research Institute

Code:

NCT07301008

Conditions

Migraine

Trigger Induced Migraine

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Rimegepant 75 MG

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-02. This information was provided to ClinicalTrials.gov by Medstar Health Research Institute on 2025-12-24.